Clinical Significance of Cyclin Expression Profiling in Ocular Surface Squamous Neoplasia.
Journal
Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796
Informations de publication
Date de publication:
01 03 2022
01 03 2022
Historique:
received:
04
08
2020
accepted:
06
09
2021
pubmed:
18
10
2021
medline:
3
5
2022
entrez:
17
10
2021
Statut:
ppublish
Résumé
Ocular surface squamous neoplasia (OSSN) can recur, metastasize, and even cause death. Cyclins regulate the cell cycle progression at different phases and its dysregulation is associated with uncontrollable cell growth and malignant transformation of the cell. Overexpression of cyclin has been reported in various malignancies and is associated with poor prognosis. However, the role of cyclins in OSSN remains unexplored. This study has been designed to assess the prognostic significance of cyclin (cyclin B1, E1, and D1) immunoexpression in 100 OSSN patients. The targeted proteins demonstrated overexpression of cyclin B1, cyclin E1, and cyclin D1 in 55%, 37%, and 56% OSSN cases prospectively. A gradual and significant increase in the cyclin B1 (P=0.01) and cyclin D1 (P=0.005) expression was seen from Tis to the T4 category. Overexpression of cyclin B1 was associated with poor disease-free survival and worst prognosis in both early (P=0.03) as well as advanced T staged (P=0.038) OSSN patients. Overexpression of cyclin E1 was associated with worst disease-free survival (P=0.01) and poor prognosis in advanced stage OSSN patients. Our findings suggest that cyclin B1 and cyclin E1 have prognostic relevance in OSSN patients, and therefore are recommended for detecting high-risk category cases. A significant increase in the expression of cyclins from early to advanced stage indicates that cyclins play an important role in the pathogenesis of OSSN patients.
Identifiants
pubmed: 34657082
doi: 10.1097/PAI.0000000000000981
pii: 00129039-202203000-00007
doi:
Substances chimiques
Cyclin B1
0
Cyclin D1
136601-57-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
197-203Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Ng J, Coroneo MT, Wakefield D, et al. Ultraviolet radiation and the role of matrix metalloproteinases in the pathogenesis of ocular surface squamous neoplasia. Invest Ophthalmol Vis Sci. 2008;49:5295–5306.
Hahn WC, Weinberg RA. Rules for making human tumor cells. N Eng J Med. 2002;347:1593–1603.
Saarilahti K, Kajanti M, Kouri M, et al. Cyclin A and Ki-67 expression as predictors for locoregional recurrence and outcome in laryngeal cancer patients treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:986–995.
Li J, Meyer AN, Donoghue DJ. Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation. Proc Natl Acad Sci USA. 1997;94:502–507.
Kawamoto H, Koizumi H, Uchikoshi T. Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant breast lesions. Am J Pathol. 1997;150:15–23.
Kushner J, Bradley G, Young B, et al. Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma. J Oral Pathol Med. 1999;28:77–81.
Hassan KA, Ang KK, El-Naggar AK, et al. Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res. 2002;62:6414–6417.
Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. Engl J Med. 2002;347:1566–1575.
Quade BJ, Park JJ, Crum CP, et al. In vivo cyclin E expression as a marker for early cervical neoplasia. Mod Pathol. 1998;11:1238–1246.
Courjal F, Louason G, Speiser P, et al. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer. 1996;69:247–253.
Wang A, Yoshimi N, Suzui M, et al. Different expression patterns of cyclins A, D1 and E in human colorectal cancer. J Cancer Res Clin Oncol. 1996;122:122–126.
Mashal RD, Lester S, Corless C, et al. Expression of cell cycle- regulated proteins in prostate cancer. Cancer Res. 1996;56:4159–4163.
Kato JY, Sherr CJ. Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. Proc Natl Acad Sci USA. 1993;90:11513–D17.
Bertoni F, Rinaldi A, Zucca E, et al. Update on the molecular biology of mantle cell lymphoma. Hematol Oncol. 2006;24:22–27.
Gautschi O, Ratschiller D, Gugger M, et al. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer. 2007;55:1–14.
Li R, An SJ, Chen ZH, et al. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. Hum Pathol. 2008;39:1792–1801.
Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol. 2005;23:4215–4224.
Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol. 2005;86:347–363.
Musgrove EA, Caldon CE, Barraclough J, et al. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558–572.
Conway RM, Graue GF, Pelayes DE, Pe’er J, Wilson MW, Christian W, Wittekind Coupland SE, Finger PT, eds. Conjunctival carcinoma. In: American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual, 8th ed. Switzerland: Springer; 2017:787–793.
Spencer WH Spencer WH. Conjunctiva. Ophthlamic Pathology: An Atlas and Textbook, 4th ed. Philadelphia, PA: WB Saunders; 1996:113–116.
Chauhan S, Sen S, Sharma A, et al. p16 INK4a overexpression as a predictor of survival in ocular surface squamous neoplasia. Br J Ophthalmol. 2018;102:840–847.
Nozoe T, Korenaga D, Kabashima A, et al. Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin Cancer Res. 2002;8:817–822.
Kourea HP, Cordon-Cardo C, Dudas M, et al. Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol. 1999;155:1885–1891.
Ives Aguilera NS, Bijwaard KE, Duncan B, et al. Taubenberger, differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin’s lymphomas. Am J Pathol. 1998;153:1969–1976.
Aaltonen K, Amini RM, Heikkilä P, et al. High cyclin B1 expression is associated with poor survival in breast cancer. Br J Cancer. 2009;100:1055–1060.
Dong Y, Sui L, Tai Y, et al. Prognostic significance of cyclin E overexpression in laryngeal squamous cell carcinomas. Clin Cancer Res. 2000;6:4253–4258.
Dhingra V, Verma J, Misra V, et al. Evaluation of cyclin D1 expression in head and neck squamous cell carcinoma. J Clin Diagn Res. 2017;11:EC01–EC04.
Soria JC, Jang SJ, Khuri FR, et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res. 2000;60:4000–4004.
Wang A, Yoshimi N, Ino N, et al. Overexpression of cyclin B1 in human colorectal cancers. J Cancer Res Clin Oncol. 1997;123:124–127.
Murakami H, Furihata M, Ohtusi Y, et al. Determination of the prog- nostic significance of cyclin B1 overexpression in patients with oesophageal squamous cell carcinom a . Virchows Arch. 1999;434:153–158.
Mishina T, Dosaka-Akita H, Hommura F, et al. Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin Cancer Res. 2000;6:11–16.
Matsumoto M, Furihata M, Ohtsuki Y, et al. Immunohistochemical characterization of p57KIP2 expression in human esophageal squamous cell carcinoma. Anticancer Res. 2000;20:1947–1952.
Eguchi N, Fujii K, Tsuchida A, et al. Cyclin E overexpression in human gallbladder carcinomas. Oncol Rep. 1999;6:93–96.
Ito Y, Matsuura N, Sakon M, et al. Expression and prognostic roles of the G1–S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology. 1999;30:90–99.
Tzankov A, Zimpfer A, Lugli A, et al. High-through-put tissue microarray analysis of G1-cyclin alterations in classical Hodgkin’s lymphoma indicates overexpression of cyclin E1. J Pathol. 2003;199:201–207.
Nielsen NH, Arnerlov C, Emdin SO, et al. Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer. 1996;74:874–880.
Sakaguchi T, Watanabe A, Sawada H, et al. Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer (Phila). 1998;82:239–1243.
Santarius T, Shipley J, Brewer D, et al. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer. 2010;10:59–64.
Hardisson D. Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2003;260:502–508.
Comstock CES, Augello MA, Benito RP, et al. Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res. 2009;15:5338–5349.
Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23:6333–6338.
Michalides R, Hageman P, Vantinteren H, et al. A clinicopathological study on overexpression of cyclinD1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer. 1996;73:728–734.
Van Diest PJ, Michalides RJ, Jannink L, et al. CyclinD1 expression in invasive breast cancer: correlations and prognostic value. Am J Pathol. 1997;150:705–711.
Ahn MJ, Kim BH, Jang SJ, et al. Expression of cyclin D1 and cyclin E in human gastric carcinoma and its clinicopathologic significance. J Korean Med Sci. 1998;13:513–518.
Shariat SF, Ashfaq R, Sagalowsky AI, et al. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol. 2006;37:1568–1576.
Bhalla K, Liu WJ, Thompson K, et al. Cyclin D1 represses gluconeogenesis via inhibition of the transcriptional coactivator PGC1α. Diabetes. 2014;63:3266–3278.